Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck & Co, Pfizer Ertugliflozin Combo Data Beef Up Profile

Executive Summary

Merck & Co and Pfizer release new combo data for their investigational SGLT2 inhibitor at the ADA – combinations will be key to the latecomer's overall success.


Related Content

FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
Considering The Value Of Cardiovascular Data And Real World Evidence In Diabetes
CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?
ADA: Diabetes Duo Merck & Pfizer Report Positive PhIII Data For Investigational SGLT-2


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts